Athira Pharma (ATHA) News Today $0.27 +0.00 (+0.15%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.30%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Moderna (NASDAQ:MRNA) & Athira Pharma (NASDAQ:ATHA) Financial ComparisonMay 21 at 2:01 AM | americanbankingnews.comAthira Pharma to present data from first-in-human Phase 1 trial of ATH-1105May 14, 2025 | finance.yahoo.comAthira Pharma (ATHA) Projected to Post Earnings on WednesdayMay 14, 2025 | americanbankingnews.comAthira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development SummitMay 13, 2025 | globenewswire.comAthira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business UpdatesMay 10, 2025 | finanznachrichten.deAthira Pharma Reports Reduced Losses and Strategic FocusMay 10, 2025 | tipranks.comAthira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business UpdatesMay 9, 2025 | globenewswire.comAthira Pharma Inc.May 3, 2025 | barrons.comAthira Pharma shifts to Nasdaq Capital Market amid compliance bidApril 18, 2025 | investing.comAthira Pharma’s 2024 Financial Results and Pipeline ProgressFebruary 28, 2025 | tipranks.comAthira Pharma (ATHA) Gets a Hold from JMP SecuritiesFebruary 28, 2025 | markets.businessinsider.comAthira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business UpdatesFebruary 27, 2025 | globenewswire.comAlterity surges after mid-stage trial data for lead assetJanuary 30, 2025 | seekingalpha.comCan Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth?January 28, 2025 | finance.yahoo.comATHA Energy expands uranium potential at AngilakJanuary 15, 2025 | proactiveinvestors.comAthira Pharma to pay $4M to settle False Claims Act allegationsJanuary 8, 2025 | markets.businessinsider.comBothell's Athira Pharma to pay $4M to settle falsified research claimsJanuary 8, 2025 | bizjournals.comBothell pharma company to pay $4 million over falsified research claimsJanuary 7, 2025 | msn.comAthira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 SharesJanuary 4, 2025 | insidertrades.comAthira Pharma Insider Ups Holding By 111% During YearDecember 18, 2024 | finance.yahoo.comAthira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MNDDecember 6, 2024 | globenewswire.comATHA Energy identifies high-grade uranium mineralization in new outcrops at AngilakDecember 5, 2024 | proactiveinvestors.comATHA Energy reveals updated technical report for Angilak uranium projectNovember 25, 2024 | proactiveinvestors.comAthira Pharma’s Regulatory Compliance Challenges Threaten Drug Development PipelineNovember 9, 2024 | tipranks.comAthira exploring strategic alternatives after Alzheimer’s failureNovember 8, 2024 | finance.yahoo.comJMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)November 8, 2024 | markets.businessinsider.comAthira Pharma Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comAthira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business UpdatesNovember 7, 2024 | globenewswire.comUS Penny Stocks: November 2024's Top Picks To ConsiderNovember 4, 2024 | finance.yahoo.comAthira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News SummaryNovember 3, 2024 | benzinga.comAthira Pharma to present results from Phase 2/3 LIFT-AD trialOctober 22, 2024 | markets.businessinsider.comAthira Pharma files $300M mixed securities shelfOctober 22, 2024 | markets.businessinsider.comMizuho Downgrades Athira Pharma (ATHA)September 20, 2024 | msn.comHold Rating on Athira Pharma Amid Strategic Pivot and Clinical UncertaintySeptember 18, 2024 | markets.businessinsider.comAthira Pharma to Cut About 70% of WorkforceSeptember 17, 2024 | marketwatch.comAthira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical ProgressSeptember 17, 2024 | markets.businessinsider.comAthira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesSeptember 17, 2024 | globenewswire.comJMP Securities Downgrades Athira Pharma (ATHA)September 5, 2024 | msn.comBTIG Downgrades Athira Pharma (ATHA)September 5, 2024 | msn.comAthira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock SinksSeptember 4, 2024 | benzinga.comAthira Pharma (NASDAQ:ATHA) Stock Rating Lowered by Rodman & RenshawRodman & Renshaw lowered shares of Athira Pharma from a "buy" rating to a "neutral" rating in a research report on Wednesday.September 4, 2024 | marketbeat.comAthira Pharma (ATHA) was downgraded to a Hold Rating at JMP SecuritiesSeptember 4, 2024 | markets.businessinsider.comStocks to Watch: Sportsman's Warehouse Holdings, PagerDuty, Athira PharmaSeptember 3, 2024 | marketwatch.comAthira Shares Plunge After Phase 2/3 Fosgonimeton Trial For Alzheimer's Fails To Meet EndpointsSeptember 3, 2024 | markets.businessinsider.comAthira stock craters 72% on failed study for Alzheimer's drugSeptember 3, 2024 | seekingalpha.comAthira Pharma Alzheimer's Treatment Trial Misses Primary EndpointSeptember 3, 2024 | marketwatch.comAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s DiseaseSeptember 3, 2024 | finance.yahoo.comAthira Pharma's Alzheimer's drug fails in mid-to-late stage trialSeptember 3, 2024 | reuters.comAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's DiseaseSeptember 3, 2024 | globenewswire.comAthira Pharma Inc Ordinary SharesAugust 31, 2024 | morningstar.com Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHA Media Mentions By Week ATHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHA News Sentiment▼0.000.65▲Average Medical News Sentiment ATHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHA Articles This Week▼11▲ATHA Articles Average Week Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VNRX News Today NRXP News Today QNCX News Today KRON News Today RANI News Today ATRA News Today ITRM News Today LTRN News Today SPRO News Today PLUR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
